YosephVision
2021-04-27
Need to check the company profile though
5 Small-Cap Stocks With 60% to 140% Upside, According to Wall Street<blockquote>华尔街称5只小盘股上涨60%至140%</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
4
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":377596054,"tweetId":"377596054","gmtCreate":1619533893578,"gmtModify":1634211975850,"author":{"id":3580867776029771,"idStr":"3580867776029771","authorId":3580867776029771,"authorIdStr":"3580867776029771","name":"YosephVision","avatar":"https://static.tigerbbs.com/8033d315729f5dbbb28d9cdc11908fc3","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Need to check the company profile though</p></body></html>","htmlText":"<html><head></head><body><p>Need to check the company profile though</p></body></html>","text":"Need to check the company profile though","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/377596054","repostId":1112397012,"repostType":4,"repost":{"id":"1112397012","kind":"news","pubTimestamp":1619521537,"share":"https://www.laohu8.com/m/news/1112397012?lang=zh_CN&edition=full","pubTime":"2021-04-27 19:05","market":"us","language":"en","title":"5 Small-Cap Stocks With 60% to 140% Upside, According to Wall Street<blockquote>华尔街称5只小盘股上涨60%至140%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1112397012","media":"Motley Fool","summary":"For more than a year, investors have been spoiled by an epic rally on Wall Street. After losing 34% ","content":"<p>For more than a year, investors have been spoiled by an epic rally on Wall Street. After losing 34% of its value in a span of just 33 calendar days in the first quarter of 2020, the benchmark<b>S&P 500</b>has roared back to gain 87% since hitting its bear-market bottom on March 23, 2020, through this past weekend.</p><p><blockquote>一年多来，投资者一直被华尔街史诗般的反弹宠坏了。在2020年第一季度短短33个日历日内损失了34%的价值后，该基准<b>标普500</b>自2020年3月23日触及熊市底部以来，截至上周末，股价已飙升87%。</blockquote></p><p>Though large-cap stocks (companies with market caps of at least $10 billion) have been the stars of this rally, it'ssmall-cap stocks($300 million to $2 billion market cap) that Wall Street believes are ready to shine. Small-caps are typically riskier in that their operating models aren't time-tested or proven. But they can usually deliver superior growth prospects compared to more mature companies.</p><p><blockquote>尽管大盘股（市值至少100亿美元的公司）一直是这次反弹的明星，但华尔街认为小盘股（市值3亿至20亿美元）已经准备好大放异彩。小盘股通常风险更大，因为它们的运营模式未经时间考验或验证。但与更成熟的公司相比，它们通常可以提供更好的增长前景。</blockquote></p><p>Based on the consensus one-year price targets of Wall Street analysts, the following five small-cap stocks all offer upside ranging from 60% to as much as 140%.</p><p><blockquote>根据华尔街分析师一致的一年目标价，以下五只小盘股均提供60%至高达140%的上涨空间。</blockquote></p><p><img src=\"https://static.tigerbbs.com/e84aa34310d37f1ab30212f9dcf1bf0d\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p>IMAGE SOURCE: GETTY IMAGES.</p><p><blockquote>图片来源：盖蒂图片社。</blockquote></p><p>Vaxart: Implied upside of 140%</p><p><blockquote>Vaxart：隐含上涨140%</blockquote></p><p>There are close to 2,000 small-cap stocks and securities for investors to choose from. However, Wall Street professionals believe you'll have a hard time topping thepotential 140% return over the next yearfrom clinical-stage biotech stock<b>Vaxart</b>(NASDAQ:VXRT).</p><p><blockquote>有近2000只小盘股和证券可供投资者选择。然而，华尔街专业人士认为，明年临床阶段生物技术股票的潜在回报率将很难超过140%<b>Vaxart</b>（纳斯达克：VXRT）。</blockquote></p><p>The Vaxart rags-to-riches story will come down to how well the company's coronavirus disease 2019 (COVID-19) treatment option, VXA-CoV2-1, fares in clinical studies. What makes this treatment so unique is that it's a tablet, rather than a shot, which could play a key role in overcoming vaccine resistance and administration. After all, you don't need trained medical personnel to administer to a tablet.</p><p><blockquote>Vaxart白手起家的故事将取决于该公司的冠状病毒疾病2019（COVID-19）治疗方案VXA-CoV2-1在临床研究中的表现。这种治疗方法的独特之处在于它是一种药片，而不是一种注射，可以在克服疫苗耐药性和给药方面发挥关键作用。毕竟，你不需要训练有素的医务人员来给药片服用。</blockquote></p><p>At the beginning of February, Vaxart announced a positive first step for VXA-CoV2-1 in a phase 1 trial. Preliminary data showed it had reached all of its primary and secondary safety and immunogenicity endpoints. Plus, there were early signs it could be effective against the original and variant strains of COVID-19.</p><p><blockquote>2月初，Vaxart宣布VXA-CoV2-1在1期试验中迈出了积极的第一步。初步数据显示，它已达到所有主要和次要安全性和免疫原性终点。此外，有早期迹象表明它可能对新冠肺炎的原始和变异毒株有效。</blockquote></p><p>It'sfar too early to tellif Vaxart's oral COVID-19 treatment will be a success in mid-or-late-stage trials, but it certainly offers game-changing potential if it is effective.</p><p><blockquote>现在判断Vaxart的口服COVID-19治疗是否会在中期或后期试验中取得成功还为时过早，但如果有效，它肯定会提供改变游戏规则的潜力。</blockquote></p><p><img src=\"https://static.tigerbbs.com/9c2902426a62a08435f7d40bec78432d\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p>IMAGE SOURCE: GETTY IMAGES.</p><p><blockquote>图片来源：盖蒂图片社。</blockquote></p><p>Harvest Health & Recreation: Implied upside of 90%</p><p><blockquote>Harvest Health&Recreation：隐含上涨90%</blockquote></p><p>With cannabis expected to be a major growth trend this decade, perhaps it's no surprise to find a lofty 12-month price target assigned to U.S. multistate operator (MSO)<b>Harvest Health & Recreation</b>(OTC:HRVSF). If Wall Street's price target is accurate, Harvest Health could gain 90% over the next year.</p><p><blockquote>由于大麻预计将成为本十年的主要增长趋势，因此为美国多州运营商(MSO)设定较高的12个月价格目标也许并不奇怪<b>收获健康与娱乐</b>（场外交易代码：HRVSF）。如果华尔街的目标价准确，Harvest Health明年可能会上涨90%。</blockquote></p><p>Unlike most U.S. MSOs, Harvest Health was a bit too wide-eyed in 2019 and overextended itself. After terminating a handful of deals and raising capital, the company is nowon trackto potentially eke out a profit in 2021 on an estimated $380 million in full-year sales. For context, this represents implied sales growth of 64%.</p><p><blockquote>与大多数美国MSO不同，Harvest Health在2019年有点睁大了眼睛，过度扩张了自己。在终止了一些交易并筹集资金后，该公司现在有望在2021年实现盈利，预计全年销售额为3.8亿美元。就上下文而言，这意味着隐含销售额增长64%。</blockquote></p><p>Currently, the company has 37 operational retail locations in five states, with a core focus on four markets: Arizona, Florida, Maryland, and Pennsylvania. Florida is raking in big bucks despite only being legal for medical marijuana, while Pennsylvania is a limited license state, which should provide some degree of competitive protection for the company as it aims to gobble up share. But with15 stores open its home state of Arizona, the Grand Canyon State represents Harvest Health's greatest opportunity.</p><p><blockquote>目前，该公司在五个州拥有37个运营零售点，核心关注四个市场：亚利桑那州、佛罗里达州、马里兰州和宾夕法尼亚州。尽管医用大麻仅合法，但佛罗里达州仍赚了很多钱，而宾夕法尼亚州是一个有限许可州，这应该会为该公司提供一定程度的竞争保护，因为该公司的目标是吞噬份额。但随着15家商店在其家乡亚利桑那州开业，大峡谷州代表着Harvest Health最大的机会。</blockquote></p><p>Though it'll have to prove to investors that it's overcome its early operating missteps, Harvest Health looks to be on its way to \"going green\" in 2021.</p><p><blockquote>尽管Harvest Health必须向投资者证明它已经克服了早期的运营失误，但它看起来将在2021年“走向绿色”。</blockquote></p><p><img src=\"https://static.tigerbbs.com/c13ce819ae0ba9b6755b8d61f6584bbc\" tg-width=\"700\" tg-height=\"439\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p>IMAGE SOURCE: GETTY IMAGES.</p><p><blockquote>图片来源：盖蒂图片社。</blockquote></p><p>EverQuote: Implied upside of 83%</p><p><blockquote>EverQuote：隐含上涨83%</blockquote></p><p>Another small-cap stock with serious upside potential is online insurance marketplace provider<b>EverQuote</b>(NASDAQ:EVER). Based on a consensus price target of $61.58, EverQuote could gain up to 83% over the next year, if analysts are accurate.</p><p><blockquote>另一只具有巨大上涨潜力的小盘股是在线保险市场提供商<b>EverQuote</b>（纳斯达克：永远不会）。如果分析师准确的话，根据61.58美元的一致目标价，EverQuote明年的涨幅可能高达83%。</blockquote></p><p>Talking about anything having to do with insurance is usually enough to put people to sleep. EverQuote aims to change that with its online marketplace where consumers can quickly and easily get price policies from leading insurance providers. According to the company, 1 in 5 consumers ends up purchasing a policy on its platform, which demonstrates that its shoppers tend to be motivated. In other words, insurers are getting more bang for their advertising buck by entrusting EverQuote's marketplace.</p><p><blockquote>谈论任何与保险有关的事情通常足以让人昏昏欲睡。EverQuote旨在通过其在线市场改变这种状况，消费者可以快速轻松地从领先的保险提供商那里获得价格政策。据该公司称，五分之一的消费者最终会在其平台上购买保单，这表明其购物者往往有积极性。换句话说，保险公司通过委托EverQuote的市场获得了更大的广告收益。</blockquote></p><p></p><p>According to the company, digital insurance ad spending isexpected to grow by 16% annuallyover the next four years. By comparison, total ad and distribution spending for the insurance industry, including digital spending, is only forecast to grow by 4% annually through 2024. EverQuote is catering to the sweet spot of insurance industry growth.</p><p><blockquote>据该公司称，未来四年数字保险广告支出预计将每年增长16%。相比之下，保险业的广告和分销总支出（包括数字支出）预计到2024年每年仅增长4%。EverQuote正在迎合保险业增长的最佳点。</blockquote></p><p>It's also a company that'sbeen transitioning to new verticals. Even though auto insurance has always been its marketplace bread-and-butter, it's added home, renters, health, and life insurance options in recent years. These new verticals are growing at a much faster clip than traditional auto policies.</p><p><blockquote>它也是一家一直在向新的垂直行业转型的公司。尽管汽车保险一直是其市场的支柱，但近年来它增加了房屋、租房、健康和人寿保险选项。这些新的垂直行业的增长速度比传统的汽车政策快得多。</blockquote></p><p><img src=\"https://static.tigerbbs.com/f46d76c781cc47d68033914c1c794a63\" tg-width=\"700\" tg-height=\"467\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p>IMAGE SOURCE: GETTY IMAGES.</p><p><blockquote>图片来源：盖蒂图片社。</blockquote></p><p>Jushi Holdings: Implied upside of 60%</p><p><blockquote>巨石控股：隐含上涨空间60%</blockquote></p><p>Just in case you didn't catch the emphasis the first time around, Wall Street is really upbeat on most U.S.marijuana stocksover the next 12 months. Small-cap MSO<b>Jushi Holdings</b>(OTC:JUSHF)is no exception. If Jushi does hit Wall Street's price target, it'll be rewarding its shareholders with a gain of 60%.</p><p><blockquote>以防你第一次没有抓住重点，华尔街对未来12个月的大多数美国大麻股票非常乐观。小盘股MSO<b>巨石控股</b>（场外交易代码：JUSHF）也不例外。如果巨石确实达到华尔街的目标价，它将为股东带来60%的收益。</blockquote></p><p>Whereas Harvest Health is focusing on four markets, Jushi isprimarily honed in on three: Pennsylvania, Illinois, and Virginia. Though it has a presence in around a half-dozen states, this trio limits how it assigns retail licenses. Pennsylvania and Illinois have capped the number of allowed dispensaries, whereas Virginia assigns licenses by jurisdiction. The takeaway is that Jushi is going to have a solid opportunity to build up its business in these states while facing minimal competition.</p><p><blockquote>Harvest Health专注于四个市场，而巨石则主要专注于三个市场：宾夕法尼亚州、伊利诺伊州和弗吉尼亚州。尽管它在大约六个州都有业务，但这三个州限制了它分配零售许可证的方式。宾夕法尼亚州和伊利诺伊州限制了允许的药房数量，而弗吉尼亚州则按司法管辖区分配许可证。结论是，巨石将有一个坚实的机会在这些州建立业务，同时面临最小的竞争。</blockquote></p><p>This is a company that hasn't been afraid to put its capital to work, either. It's made a host of acquisitions since the year began, including expanding its retail or cultivation footprint in Massachusetts, Ohio, Pennsylvania, and California.</p><p><blockquote>这也是一家不害怕将资本投入使用的公司。自今年年初以来，该公司进行了一系列收购，包括扩大其在马萨诸塞州、俄亥俄州、宾夕法尼亚州和加利福尼亚州的零售或种植足迹。</blockquote></p><p>If you're looking for one more catalyst, consider that executives and insiders contributed approximately $45 million of the first $250 million in capital raised. When the interests of insiders and shareholders align, we often see good things happen.</p><p><blockquote>如果您正在寻找另一个催化剂，请考虑一下高管和内部人士在最初筹集的2.5亿美元资金中贡献了约4500万美元。当内部人士和股东的利益一致时，我们经常会看到好事发生。</blockquote></p><p><img src=\"https://static.tigerbbs.com/b9ff45f54cb49bde34240fc05af21a38\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p>IMAGE SOURCE: GETTY IMAGES.</p><p><blockquote>图片来源：盖蒂图片社。</blockquote></p><p>Inovio Pharmaceuticals: Implied upside of 128%</p><p><blockquote>Inovio Pharmaceuticals：隐含上涨128%</blockquote></p><p>Finally, clinical-stagebiotech stock<b>Inovio Pharmaceuticals</b>(NASDAQ:INO)is believed to offer significant upside. Based on a 12-month price target of $15.63, Inovio's shares could more than double. But this one instance where I strongly disagree with Wall Street.</p><p><blockquote>最后，临床阶段生物技术股票<b>Inovio制药公司</b>（纳斯达克：INO）被认为具有显着的上涨空间。根据15.63美元的12个月目标价计算，Inovio的股价可能会上涨一倍以上。但这是我强烈反对华尔街的一个例子。</blockquote></p><p>For much of the past year, Inovio has flown higher on the expectation that it would be among the frontrunners to develop a COVID-19 vaccine. But despite flying though phase 1 studies, Inovio encountered a partial clinical hold in phase 2/3 trials in the United States. This past week, the company announced that its phase 3 study for INO-4800 as a treatment for COVID-19 would take place outside the U.S., and that the U.S. Defense Department would cease funding the company's late-stage studies for INO-4800.</p><p><blockquote>在过去一年的大部分时间里，Inovio股价飙升，因为人们期望它将成为开发COVID-19疫苗的领跑者之一。但尽管通过了1期研究，Inovio在美国的2/3期试验中遇到了部分临床搁置。上周，该公司宣布INO-4800治疗新冠肺炎的3期研究将在美国境外进行，美国国防部将停止资助该公司INO-4800的后期研究。</blockquote></p><p>There are reallytwo issues at hand here. First, Inovio has fallen so far behind its peers due to the Food and Drug Administration's (FDA) partial clinical hold that it may not be able to carve out a meaningful percentage of global COVID-19 vaccine sales, even if INO-4800 is successful in clinical studies.</p><p><blockquote>这里实际上有两个问题。首先，由于美国食品和药物管理局(FDA)的部分临床搁置，Inovio已经远远落后于同行，即使INO-4800在临床研究中取得成功，它也可能无法在全球COVID-19疫苗销售中占据有意义的比例。</blockquote></p><p>Secondly, Inovio has nothing to show for itself after more than four decades. In spite of plenty of ongoing research, none of the company's experimental treatments have ever been approved by the FDA. That's a pretty glaring red flag.</p><p><blockquote>其次，四十多年后，Inovio没有什么可展示的。尽管有大量正在进行的研究，但该公司的实验性治疗方法从未获得FDA的批准。这是一个非常明显的危险信号。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Small-Cap Stocks With 60% to 140% Upside, According to Wall Street<blockquote>华尔街称5只小盘股上涨60%至140%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Small-Cap Stocks With 60% to 140% Upside, According to Wall Street<blockquote>华尔街称5只小盘股上涨60%至140%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-04-27 19:05</span>\n</p>\n</h4>\n</header>\n<article>\n<p>For more than a year, investors have been spoiled by an epic rally on Wall Street. After losing 34% of its value in a span of just 33 calendar days in the first quarter of 2020, the benchmark<b>S&P 500</b>has roared back to gain 87% since hitting its bear-market bottom on March 23, 2020, through this past weekend.</p><p><blockquote>一年多来，投资者一直被华尔街史诗般的反弹宠坏了。在2020年第一季度短短33个日历日内损失了34%的价值后，该基准<b>标普500</b>自2020年3月23日触及熊市底部以来，截至上周末，股价已飙升87%。</blockquote></p><p>Though large-cap stocks (companies with market caps of at least $10 billion) have been the stars of this rally, it'ssmall-cap stocks($300 million to $2 billion market cap) that Wall Street believes are ready to shine. Small-caps are typically riskier in that their operating models aren't time-tested or proven. But they can usually deliver superior growth prospects compared to more mature companies.</p><p><blockquote>尽管大盘股（市值至少100亿美元的公司）一直是这次反弹的明星，但华尔街认为小盘股（市值3亿至20亿美元）已经准备好大放异彩。小盘股通常风险更大，因为它们的运营模式未经时间考验或验证。但与更成熟的公司相比，它们通常可以提供更好的增长前景。</blockquote></p><p>Based on the consensus one-year price targets of Wall Street analysts, the following five small-cap stocks all offer upside ranging from 60% to as much as 140%.</p><p><blockquote>根据华尔街分析师一致的一年目标价，以下五只小盘股均提供60%至高达140%的上涨空间。</blockquote></p><p><img src=\"https://static.tigerbbs.com/e84aa34310d37f1ab30212f9dcf1bf0d\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p>IMAGE SOURCE: GETTY IMAGES.</p><p><blockquote>图片来源：盖蒂图片社。</blockquote></p><p>Vaxart: Implied upside of 140%</p><p><blockquote>Vaxart：隐含上涨140%</blockquote></p><p>There are close to 2,000 small-cap stocks and securities for investors to choose from. However, Wall Street professionals believe you'll have a hard time topping thepotential 140% return over the next yearfrom clinical-stage biotech stock<b>Vaxart</b>(NASDAQ:VXRT).</p><p><blockquote>有近2000只小盘股和证券可供投资者选择。然而，华尔街专业人士认为，明年临床阶段生物技术股票的潜在回报率将很难超过140%<b>Vaxart</b>（纳斯达克：VXRT）。</blockquote></p><p>The Vaxart rags-to-riches story will come down to how well the company's coronavirus disease 2019 (COVID-19) treatment option, VXA-CoV2-1, fares in clinical studies. What makes this treatment so unique is that it's a tablet, rather than a shot, which could play a key role in overcoming vaccine resistance and administration. After all, you don't need trained medical personnel to administer to a tablet.</p><p><blockquote>Vaxart白手起家的故事将取决于该公司的冠状病毒疾病2019（COVID-19）治疗方案VXA-CoV2-1在临床研究中的表现。这种治疗方法的独特之处在于它是一种药片，而不是一种注射，可以在克服疫苗耐药性和给药方面发挥关键作用。毕竟，你不需要训练有素的医务人员来给药片服用。</blockquote></p><p>At the beginning of February, Vaxart announced a positive first step for VXA-CoV2-1 in a phase 1 trial. Preliminary data showed it had reached all of its primary and secondary safety and immunogenicity endpoints. Plus, there were early signs it could be effective against the original and variant strains of COVID-19.</p><p><blockquote>2月初，Vaxart宣布VXA-CoV2-1在1期试验中迈出了积极的第一步。初步数据显示，它已达到所有主要和次要安全性和免疫原性终点。此外，有早期迹象表明它可能对新冠肺炎的原始和变异毒株有效。</blockquote></p><p>It'sfar too early to tellif Vaxart's oral COVID-19 treatment will be a success in mid-or-late-stage trials, but it certainly offers game-changing potential if it is effective.</p><p><blockquote>现在判断Vaxart的口服COVID-19治疗是否会在中期或后期试验中取得成功还为时过早，但如果有效，它肯定会提供改变游戏规则的潜力。</blockquote></p><p><img src=\"https://static.tigerbbs.com/9c2902426a62a08435f7d40bec78432d\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p>IMAGE SOURCE: GETTY IMAGES.</p><p><blockquote>图片来源：盖蒂图片社。</blockquote></p><p>Harvest Health & Recreation: Implied upside of 90%</p><p><blockquote>Harvest Health&Recreation：隐含上涨90%</blockquote></p><p>With cannabis expected to be a major growth trend this decade, perhaps it's no surprise to find a lofty 12-month price target assigned to U.S. multistate operator (MSO)<b>Harvest Health & Recreation</b>(OTC:HRVSF). If Wall Street's price target is accurate, Harvest Health could gain 90% over the next year.</p><p><blockquote>由于大麻预计将成为本十年的主要增长趋势，因此为美国多州运营商(MSO)设定较高的12个月价格目标也许并不奇怪<b>收获健康与娱乐</b>（场外交易代码：HRVSF）。如果华尔街的目标价准确，Harvest Health明年可能会上涨90%。</blockquote></p><p>Unlike most U.S. MSOs, Harvest Health was a bit too wide-eyed in 2019 and overextended itself. After terminating a handful of deals and raising capital, the company is nowon trackto potentially eke out a profit in 2021 on an estimated $380 million in full-year sales. For context, this represents implied sales growth of 64%.</p><p><blockquote>与大多数美国MSO不同，Harvest Health在2019年有点睁大了眼睛，过度扩张了自己。在终止了一些交易并筹集资金后，该公司现在有望在2021年实现盈利，预计全年销售额为3.8亿美元。就上下文而言，这意味着隐含销售额增长64%。</blockquote></p><p>Currently, the company has 37 operational retail locations in five states, with a core focus on four markets: Arizona, Florida, Maryland, and Pennsylvania. Florida is raking in big bucks despite only being legal for medical marijuana, while Pennsylvania is a limited license state, which should provide some degree of competitive protection for the company as it aims to gobble up share. But with15 stores open its home state of Arizona, the Grand Canyon State represents Harvest Health's greatest opportunity.</p><p><blockquote>目前，该公司在五个州拥有37个运营零售点，核心关注四个市场：亚利桑那州、佛罗里达州、马里兰州和宾夕法尼亚州。尽管医用大麻仅合法，但佛罗里达州仍赚了很多钱，而宾夕法尼亚州是一个有限许可州，这应该会为该公司提供一定程度的竞争保护，因为该公司的目标是吞噬份额。但随着15家商店在其家乡亚利桑那州开业，大峡谷州代表着Harvest Health最大的机会。</blockquote></p><p>Though it'll have to prove to investors that it's overcome its early operating missteps, Harvest Health looks to be on its way to \"going green\" in 2021.</p><p><blockquote>尽管Harvest Health必须向投资者证明它已经克服了早期的运营失误，但它看起来将在2021年“走向绿色”。</blockquote></p><p><img src=\"https://static.tigerbbs.com/c13ce819ae0ba9b6755b8d61f6584bbc\" tg-width=\"700\" tg-height=\"439\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p>IMAGE SOURCE: GETTY IMAGES.</p><p><blockquote>图片来源：盖蒂图片社。</blockquote></p><p>EverQuote: Implied upside of 83%</p><p><blockquote>EverQuote：隐含上涨83%</blockquote></p><p>Another small-cap stock with serious upside potential is online insurance marketplace provider<b>EverQuote</b>(NASDAQ:EVER). Based on a consensus price target of $61.58, EverQuote could gain up to 83% over the next year, if analysts are accurate.</p><p><blockquote>另一只具有巨大上涨潜力的小盘股是在线保险市场提供商<b>EverQuote</b>（纳斯达克：永远不会）。如果分析师准确的话，根据61.58美元的一致目标价，EverQuote明年的涨幅可能高达83%。</blockquote></p><p>Talking about anything having to do with insurance is usually enough to put people to sleep. EverQuote aims to change that with its online marketplace where consumers can quickly and easily get price policies from leading insurance providers. According to the company, 1 in 5 consumers ends up purchasing a policy on its platform, which demonstrates that its shoppers tend to be motivated. In other words, insurers are getting more bang for their advertising buck by entrusting EverQuote's marketplace.</p><p><blockquote>谈论任何与保险有关的事情通常足以让人昏昏欲睡。EverQuote旨在通过其在线市场改变这种状况，消费者可以快速轻松地从领先的保险提供商那里获得价格政策。据该公司称，五分之一的消费者最终会在其平台上购买保单，这表明其购物者往往有积极性。换句话说，保险公司通过委托EverQuote的市场获得了更大的广告收益。</blockquote></p><p></p><p>According to the company, digital insurance ad spending isexpected to grow by 16% annuallyover the next four years. By comparison, total ad and distribution spending for the insurance industry, including digital spending, is only forecast to grow by 4% annually through 2024. EverQuote is catering to the sweet spot of insurance industry growth.</p><p><blockquote>据该公司称，未来四年数字保险广告支出预计将每年增长16%。相比之下，保险业的广告和分销总支出（包括数字支出）预计到2024年每年仅增长4%。EverQuote正在迎合保险业增长的最佳点。</blockquote></p><p>It's also a company that'sbeen transitioning to new verticals. Even though auto insurance has always been its marketplace bread-and-butter, it's added home, renters, health, and life insurance options in recent years. These new verticals are growing at a much faster clip than traditional auto policies.</p><p><blockquote>它也是一家一直在向新的垂直行业转型的公司。尽管汽车保险一直是其市场的支柱，但近年来它增加了房屋、租房、健康和人寿保险选项。这些新的垂直行业的增长速度比传统的汽车政策快得多。</blockquote></p><p><img src=\"https://static.tigerbbs.com/f46d76c781cc47d68033914c1c794a63\" tg-width=\"700\" tg-height=\"467\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p>IMAGE SOURCE: GETTY IMAGES.</p><p><blockquote>图片来源：盖蒂图片社。</blockquote></p><p>Jushi Holdings: Implied upside of 60%</p><p><blockquote>巨石控股：隐含上涨空间60%</blockquote></p><p>Just in case you didn't catch the emphasis the first time around, Wall Street is really upbeat on most U.S.marijuana stocksover the next 12 months. Small-cap MSO<b>Jushi Holdings</b>(OTC:JUSHF)is no exception. If Jushi does hit Wall Street's price target, it'll be rewarding its shareholders with a gain of 60%.</p><p><blockquote>以防你第一次没有抓住重点，华尔街对未来12个月的大多数美国大麻股票非常乐观。小盘股MSO<b>巨石控股</b>（场外交易代码：JUSHF）也不例外。如果巨石确实达到华尔街的目标价，它将为股东带来60%的收益。</blockquote></p><p>Whereas Harvest Health is focusing on four markets, Jushi isprimarily honed in on three: Pennsylvania, Illinois, and Virginia. Though it has a presence in around a half-dozen states, this trio limits how it assigns retail licenses. Pennsylvania and Illinois have capped the number of allowed dispensaries, whereas Virginia assigns licenses by jurisdiction. The takeaway is that Jushi is going to have a solid opportunity to build up its business in these states while facing minimal competition.</p><p><blockquote>Harvest Health专注于四个市场，而巨石则主要专注于三个市场：宾夕法尼亚州、伊利诺伊州和弗吉尼亚州。尽管它在大约六个州都有业务，但这三个州限制了它分配零售许可证的方式。宾夕法尼亚州和伊利诺伊州限制了允许的药房数量，而弗吉尼亚州则按司法管辖区分配许可证。结论是，巨石将有一个坚实的机会在这些州建立业务，同时面临最小的竞争。</blockquote></p><p>This is a company that hasn't been afraid to put its capital to work, either. It's made a host of acquisitions since the year began, including expanding its retail or cultivation footprint in Massachusetts, Ohio, Pennsylvania, and California.</p><p><blockquote>这也是一家不害怕将资本投入使用的公司。自今年年初以来，该公司进行了一系列收购，包括扩大其在马萨诸塞州、俄亥俄州、宾夕法尼亚州和加利福尼亚州的零售或种植足迹。</blockquote></p><p>If you're looking for one more catalyst, consider that executives and insiders contributed approximately $45 million of the first $250 million in capital raised. When the interests of insiders and shareholders align, we often see good things happen.</p><p><blockquote>如果您正在寻找另一个催化剂，请考虑一下高管和内部人士在最初筹集的2.5亿美元资金中贡献了约4500万美元。当内部人士和股东的利益一致时，我们经常会看到好事发生。</blockquote></p><p><img src=\"https://static.tigerbbs.com/b9ff45f54cb49bde34240fc05af21a38\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p>IMAGE SOURCE: GETTY IMAGES.</p><p><blockquote>图片来源：盖蒂图片社。</blockquote></p><p>Inovio Pharmaceuticals: Implied upside of 128%</p><p><blockquote>Inovio Pharmaceuticals：隐含上涨128%</blockquote></p><p>Finally, clinical-stagebiotech stock<b>Inovio Pharmaceuticals</b>(NASDAQ:INO)is believed to offer significant upside. Based on a 12-month price target of $15.63, Inovio's shares could more than double. But this one instance where I strongly disagree with Wall Street.</p><p><blockquote>最后，临床阶段生物技术股票<b>Inovio制药公司</b>（纳斯达克：INO）被认为具有显着的上涨空间。根据15.63美元的12个月目标价计算，Inovio的股价可能会上涨一倍以上。但这是我强烈反对华尔街的一个例子。</blockquote></p><p>For much of the past year, Inovio has flown higher on the expectation that it would be among the frontrunners to develop a COVID-19 vaccine. But despite flying though phase 1 studies, Inovio encountered a partial clinical hold in phase 2/3 trials in the United States. This past week, the company announced that its phase 3 study for INO-4800 as a treatment for COVID-19 would take place outside the U.S., and that the U.S. Defense Department would cease funding the company's late-stage studies for INO-4800.</p><p><blockquote>在过去一年的大部分时间里，Inovio股价飙升，因为人们期望它将成为开发COVID-19疫苗的领跑者之一。但尽管通过了1期研究，Inovio在美国的2/3期试验中遇到了部分临床搁置。上周，该公司宣布INO-4800治疗新冠肺炎的3期研究将在美国境外进行，美国国防部将停止资助该公司INO-4800的后期研究。</blockquote></p><p>There are reallytwo issues at hand here. First, Inovio has fallen so far behind its peers due to the Food and Drug Administration's (FDA) partial clinical hold that it may not be able to carve out a meaningful percentage of global COVID-19 vaccine sales, even if INO-4800 is successful in clinical studies.</p><p><blockquote>这里实际上有两个问题。首先，由于美国食品和药物管理局(FDA)的部分临床搁置，Inovio已经远远落后于同行，即使INO-4800在临床研究中取得成功，它也可能无法在全球COVID-19疫苗销售中占据有意义的比例。</blockquote></p><p>Secondly, Inovio has nothing to show for itself after more than four decades. In spite of plenty of ongoing research, none of the company's experimental treatments have ever been approved by the FDA. That's a pretty glaring red flag.</p><p><blockquote>其次，四十多年后，Inovio没有什么可展示的。尽管有大量正在进行的研究，但该公司的实验性治疗方法从未获得FDA的批准。这是一个非常明显的危险信号。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/04/27/5-small-cap-stocks-60-to-140-upside-wall-street/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/04/27/5-small-cap-stocks-60-to-140-upside-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112397012","content_text":"For more than a year, investors have been spoiled by an epic rally on Wall Street. After losing 34% of its value in a span of just 33 calendar days in the first quarter of 2020, the benchmarkS&P 500has roared back to gain 87% since hitting its bear-market bottom on March 23, 2020, through this past weekend.Though large-cap stocks (companies with market caps of at least $10 billion) have been the stars of this rally, it'ssmall-cap stocks($300 million to $2 billion market cap) that Wall Street believes are ready to shine. Small-caps are typically riskier in that their operating models aren't time-tested or proven. But they can usually deliver superior growth prospects compared to more mature companies.Based on the consensus one-year price targets of Wall Street analysts, the following five small-cap stocks all offer upside ranging from 60% to as much as 140%.IMAGE SOURCE: GETTY IMAGES.Vaxart: Implied upside of 140%There are close to 2,000 small-cap stocks and securities for investors to choose from. However, Wall Street professionals believe you'll have a hard time topping thepotential 140% return over the next yearfrom clinical-stage biotech stockVaxart(NASDAQ:VXRT).The Vaxart rags-to-riches story will come down to how well the company's coronavirus disease 2019 (COVID-19) treatment option, VXA-CoV2-1, fares in clinical studies. What makes this treatment so unique is that it's a tablet, rather than a shot, which could play a key role in overcoming vaccine resistance and administration. After all, you don't need trained medical personnel to administer to a tablet.At the beginning of February, Vaxart announced a positive first step for VXA-CoV2-1 in a phase 1 trial. Preliminary data showed it had reached all of its primary and secondary safety and immunogenicity endpoints. Plus, there were early signs it could be effective against the original and variant strains of COVID-19.It'sfar too early to tellif Vaxart's oral COVID-19 treatment will be a success in mid-or-late-stage trials, but it certainly offers game-changing potential if it is effective.IMAGE SOURCE: GETTY IMAGES.Harvest Health & Recreation: Implied upside of 90%With cannabis expected to be a major growth trend this decade, perhaps it's no surprise to find a lofty 12-month price target assigned to U.S. multistate operator (MSO)Harvest Health & Recreation(OTC:HRVSF). If Wall Street's price target is accurate, Harvest Health could gain 90% over the next year.Unlike most U.S. MSOs, Harvest Health was a bit too wide-eyed in 2019 and overextended itself. After terminating a handful of deals and raising capital, the company is nowon trackto potentially eke out a profit in 2021 on an estimated $380 million in full-year sales. For context, this represents implied sales growth of 64%.Currently, the company has 37 operational retail locations in five states, with a core focus on four markets: Arizona, Florida, Maryland, and Pennsylvania. Florida is raking in big bucks despite only being legal for medical marijuana, while Pennsylvania is a limited license state, which should provide some degree of competitive protection for the company as it aims to gobble up share. But with15 stores open its home state of Arizona, the Grand Canyon State represents Harvest Health's greatest opportunity.Though it'll have to prove to investors that it's overcome its early operating missteps, Harvest Health looks to be on its way to \"going green\" in 2021.IMAGE SOURCE: GETTY IMAGES.EverQuote: Implied upside of 83%Another small-cap stock with serious upside potential is online insurance marketplace providerEverQuote(NASDAQ:EVER). Based on a consensus price target of $61.58, EverQuote could gain up to 83% over the next year, if analysts are accurate.Talking about anything having to do with insurance is usually enough to put people to sleep. EverQuote aims to change that with its online marketplace where consumers can quickly and easily get price policies from leading insurance providers. According to the company, 1 in 5 consumers ends up purchasing a policy on its platform, which demonstrates that its shoppers tend to be motivated. In other words, insurers are getting more bang for their advertising buck by entrusting EverQuote's marketplace.According to the company, digital insurance ad spending isexpected to grow by 16% annuallyover the next four years. By comparison, total ad and distribution spending for the insurance industry, including digital spending, is only forecast to grow by 4% annually through 2024. EverQuote is catering to the sweet spot of insurance industry growth.It's also a company that'sbeen transitioning to new verticals. Even though auto insurance has always been its marketplace bread-and-butter, it's added home, renters, health, and life insurance options in recent years. These new verticals are growing at a much faster clip than traditional auto policies.IMAGE SOURCE: GETTY IMAGES.Jushi Holdings: Implied upside of 60%Just in case you didn't catch the emphasis the first time around, Wall Street is really upbeat on most U.S.marijuana stocksover the next 12 months. Small-cap MSOJushi Holdings(OTC:JUSHF)is no exception. If Jushi does hit Wall Street's price target, it'll be rewarding its shareholders with a gain of 60%.Whereas Harvest Health is focusing on four markets, Jushi isprimarily honed in on three: Pennsylvania, Illinois, and Virginia. Though it has a presence in around a half-dozen states, this trio limits how it assigns retail licenses. Pennsylvania and Illinois have capped the number of allowed dispensaries, whereas Virginia assigns licenses by jurisdiction. The takeaway is that Jushi is going to have a solid opportunity to build up its business in these states while facing minimal competition.This is a company that hasn't been afraid to put its capital to work, either. It's made a host of acquisitions since the year began, including expanding its retail or cultivation footprint in Massachusetts, Ohio, Pennsylvania, and California.If you're looking for one more catalyst, consider that executives and insiders contributed approximately $45 million of the first $250 million in capital raised. When the interests of insiders and shareholders align, we often see good things happen.IMAGE SOURCE: GETTY IMAGES.Inovio Pharmaceuticals: Implied upside of 128%Finally, clinical-stagebiotech stockInovio Pharmaceuticals(NASDAQ:INO)is believed to offer significant upside. Based on a 12-month price target of $15.63, Inovio's shares could more than double. But this one instance where I strongly disagree with Wall Street.For much of the past year, Inovio has flown higher on the expectation that it would be among the frontrunners to develop a COVID-19 vaccine. But despite flying though phase 1 studies, Inovio encountered a partial clinical hold in phase 2/3 trials in the United States. This past week, the company announced that its phase 3 study for INO-4800 as a treatment for COVID-19 would take place outside the U.S., and that the U.S. Defense Department would cease funding the company's late-stage studies for INO-4800.There are reallytwo issues at hand here. First, Inovio has fallen so far behind its peers due to the Food and Drug Administration's (FDA) partial clinical hold that it may not be able to carve out a meaningful percentage of global COVID-19 vaccine sales, even if INO-4800 is successful in clinical studies.Secondly, Inovio has nothing to show for itself after more than four decades. In spite of plenty of ongoing research, none of the company's experimental treatments have ever been approved by the FDA. That's a pretty glaring red flag.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":709,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":34,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/377596054"}
精彩评论